Avidity Partners 13F holdings, Q1 2025
Holdings as of March 31, 2025 · filings on SEC EDGAR · latest filing →
Avidity Partners disclosed 63 US equity positions worth $484.9m in its Q1 2025 13F filing. The largest position was BSX at 7.0% of the reported book, followed by DNTH and UNH. Against the Q4 2024 filing, it opened 13 new positions, added to 3 and reduced 31 among the top 50 holdings.
What did Avidity Partners own in Q1 2025? Top 50 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q4 2024 |
|---|---|---|---|---|---|---|---|
| 1 | BSX BOSTON SCIENTIFIC CORP | Healthcare | 7.0% | $33.9m | 336,000 | -35% | reduced |
| 2 | DNTH DIANTHUS THERAPEUTICS INC | Healthcare | 6.4% | $31.2m | 1,720,902 | -40% | reduced |
| 3 | UNH UNITEDHEALTH GROUP INC | Healthcare | 5.5% | $26.4m | 50,500 | -16% | reduced |
| 4 | CGON CG ONCOLOGY INC | Healthcare | 5.0% | $24.0m | 980,942 | -11% | reduced |
| 5 | HUM HUMANA INC | Healthcare | 4.4% | $21.4m | 81,000 | -9% | reduced |
| 6 | NTRA NATERA INC | Healthcare | 3.5% | $16.9m | 119,200 | -47% | reduced |
| 7 | REGN REGENERON PHARMACEUTICALS | Healthcare | 3.3% | $16.1m | 25,400 | 202% | added |
| 8 | EXK EXACT SCIENCES CORP | Basic Materials | 3.2% | $15.3m | 353,000 | -41% | reduced |
| 9 | BEAM BEAM THERAPEUTICS INC | Healthcare | 2.9% | $13.9m | 709,517 | – | new |
| 10 | GKOS GLAUKOS CORP | Healthcare | 2.7% | $13.2m | 134,000 | -21% | reduced |
| 11 | DXCM DEXCOM INC | Healthcare | 2.5% | $12.3m | 180,000 | -43% | reduced |
| 12 | RARE ULTRAGENYX PHARMACEUTICAL IN | Healthcare | 2.4% | $11.7m | 322,100 | -8% | reduced |
| 13 | SNDX SYNDAX PHARMACEUTICALS INC | Healthcare | 2.3% | $11.4m | 925,000 | -38% | reduced |
| 14 | COR CENCORA INC | Healthcare | 2.3% | $10.9m | 39,300 | – | new |
| 15 | JAZZ JAZZ PHARMACEUTICALS PLC | Healthcare | 2.0% | $9.9m | 80,000 | -66% | reduced |
| 16 | THC TENET HEALTHCARE CORP | Healthcare | 2.0% | $9.7m | 72,000 | -47% | reduced |
| 17 | NBIX NEUROCRINE BIOSCIENCES INC | Healthcare | 2.0% | $9.5m | 85,700 | -61% | reduced |
| 18 | DHR DANAHER CORPORATION | Healthcare | 1.9% | $9.1m | 44,500 | -34% | reduced |
| 19 | AXSM AXSOME THERAPEUTICS INC | Healthcare | 1.9% | $9.0m | 77,000 | -59% | reduced |
| 20 | INSM INSMED INC | Healthcare | 1.7% | $8.2m | 107,000 | -54% | reduced |
| 21 | OGN ORGANON & CO | Healthcare | 1.6% | $8.0m | 535,000 | – | new |
| 22 | TMO THERMO FISHER SCIENTIFIC INC | Healthcare | 1.6% | $7.7m | 15,500 | -65% | reduced |
| 23 | XENE XENON PHARMACEUTICALS INC | Healthcare | 1.6% | $7.7m | 229,000 | -52% | reduced |
| 24 | XBI SPDR SER TR | 1.6% | $7.6m | 94,000 | – | new | |
| 25 | CNTA CENTESSA PHARMACEUTICALS PLC | 1.6% | $7.6m | 529,000 | -55% | reduced | |
| 26 | RVMD REVOLUTION MEDICINES INC | Healthcare | 1.6% | $7.5m | 213,000 | -52% | reduced |
| 27 | TEVA TEVA PHARMACEUTICAL INDS LTD | Healthcare | 1.5% | $7.4m | 481,000 | – | new |
| 28 | AVTR AVANTOR INC | Healthcare | 1.5% | $7.3m | 453,000 | -52% | reduced |
| 29 | IDYA IDEAYA BIOSCIENCES INC | Healthcare | 1.5% | $7.3m | 445,000 | -61% | reduced |
| 30 | DOCS DOXIMITY INC | Healthcare | 1.5% | $7.1m | 122,500 | – | new |
| 31 | JANX JANUX THERAPEUTICS INC | Healthcare | 1.4% | $7.0m | 258,000 | -65% | reduced |
| 32 | HQY HEALTHEQUITY INC | Healthcare | 1.4% | $6.9m | 78,000 | – | new |
| 33 | 2655787D BLUEPRINT MEDICINES CORP | 1.3% | $6.1m | 68,500 | -61% | reduced | |
| 34 | UTHR UNITED THERAPEUTICS CORP DEL | Healthcare | 1.1% | $5.2m | 16,800 | – | new |
| 35 | PHAT PHATHOM PHARMACEUTICALS INC | 1.0% | $5.0m | 800,000 | -42% | reduced | |
| 36 | IMUX IMMUNIC INC | Healthcare | 1.0% | $4.9m | 4,454,408 | -44% | reduced |
| 37 | BRKR BRUKER CORP | Healthcare | 1.0% | $4.8m | 115,000 | 51% | added |
| 38 | CATX PERSPECTIVE THERAPEUTICS INC | 1.0% | $4.7m | 2,197,270 | -18% | reduced | |
| 39 | CNTX CONTEXT THERAPEUTICS INC | 0.9% | $4.6m | 7,477,200 | 0% | held | |
| 40 | ORKA ORUKA THERAPEUTICS INC | Healthcare | 0.7% | $3.6m | 352,124 | 0% | held |
| 41 | UNIQURE NV | 0.7% | $3.6m | 336,200 | 51% | added | |
| 42 | BHVN BIOHAVEN LTD | Healthcare | 0.7% | $3.5m | 145,000 | -35% | reduced |
| 43 | ARVN ARVINAS INC | Healthcare | 0.6% | $2.9m | 413,162 | -70% | reduced |
| 44 | ACAD ACADIA PHARMACEUTICALS INC | Healthcare | 0.6% | $2.8m | 169,000 | – | new |
| 45 | RPRX ROYALTY PHARMA PLC | Healthcare | 0.6% | $2.7m | 87,000 | – | new |
| 46 | BBIO BRIDGEBIO PHARMA INC | Healthcare | 0.5% | $2.6m | 75,000 | – | new |
| 47 | KEZAR LIFE SCIENCES INC | 0.5% | $2.5m | 502,600 | 0% | held | |
| 48 | AKERO THERAPEUTICS INC | 0.5% | $2.3m | 57,000 | -30% | reduced | |
| 49 | SOLENO THERAPEUTICS INC | 0.5% | $2.3m | 32,000 | – | new | |
| 50 | CAPR CAPRICOR THERAPEUTICS INC | Healthcare | 0.5% | $2.3m | 239,000 | – | new |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.